VelaShape and Contour I V3 for Abdominal Fat Reduction vs. Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-10

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, 2-arm, clinical study for the evaluation of the VelaShape device and Contour I V3 device for non-invasive fat reduction vs. control.

All study subjects, who are scheduled for abdominoplasty, will undergo one treatment with VelaShape or Contour I V3 device.

Each arm will be treated with a different device:

Arm 1: subject will treated with VelaShape device Arm 2: subject will treated with Contour I V3 device

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction

NCT02143960

Abdominal Fat

COMPLETED NA

Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction

NCT02154113

Abdominal Fat

COMPLETED NA

A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference

NCT01462201

Body Sculpting

COMPLETED NA

Non-Invasive Abdominal Fat Reduction With BMI Above 28

NCT02711618

Unwanted Fat

UNKNOWN NA

SlimShape Device for Abdominal Fat and Circumference Reduction

NCT02999763

Fat Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible subjects will undergo one treatment on one abdominal subarea. Another abdominal subarea will remain without treatment and will serve as a control. Biopsies from treated and untreated areas will be harvested during abdominoplasty and cultured.. Treatment with VelaShape will be performed to arm 1, and treatment with Contour I V3 will be performed to arm 2, according to the study protocol.

Each arm will be divided into 6 sub-groups, according to the following time interval between VelaShape or UltraShape treatment to surgery:

Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment Each Sub-group contains up to 2 subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unwanted Abdomen Fat

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment with VelaShape device

One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:

Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment

Group Type EXPERIMENTAL

VelaShape device

Intervention Type DEVICE

Modified VelaShape radiofrequency device for non invasive fat reduction treatment.

Treatment with Contour I V3 device

One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:

Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment

Group Type EXPERIMENTAL

Contour I V3 device

Intervention Type DEVICE

Contour I V3 device are non invasive for fat reduction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VelaShape device

Modified VelaShape radiofrequency device for non invasive fat reduction treatment.

Intervention Type DEVICE

Contour I V3 device

Contour I V3 device are non invasive for fat reduction.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent to participate in the study.
2. Scheduled date for surgery (abdominoplasty).
3. Agree to provide samples for histology from the abdominoplasty.
4. Female and male subjects, between 18 to 60 years of age at the time of enrollment
5. Fitzpatrick Skin Type I to VI.
6. For Contour I V3 treatment only: Abdominal fat thickness of at least 1.5 cm (measured by calibrated caliper).
7. Female subjects must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
8. General good health confirmed by medical history and skin examination of the treated area.
9. Willing to follow the treatment and to provide histology samples during the surgery from the intended to be harvested areas.
10. Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
11. Willing to have photographs and images taken of the treated areas to be used (with de-identification) in evaluations, publications and presentations

Exclusion Criteria

1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, or abdominal aortic aneurism
2. Not intended to undergo surgery (abdominoplasty)
3. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
4. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
5. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
6. Having a permanent implant in the treated area, such as metal plates, or an injected chemical substance such as silicone
7. Having undergone any other surgery in the treatment area within 12 months of treatment or during the study, including liposuction
8. Previous body contouring procedures in the treatment area within 12 months
9. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing Known photosensitivity
10. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
11. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
12. Very poor skin quality (i.e., severe laxity)
13. Abdominal wall diastasis or hernia on physical examination
14. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
15. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study
16. Unstable weight within the last 6 months (i.e., more than ± 3% weight change in the prior 6 months)
17. Participation in another clinical study within the last 6 months.
18. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes